^
Association details:
| Biomarker: | Chr del(17p) |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Elrexfio (elranatamab-bcmm) (CD3 agonist, BCMA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and safety of elranatamab in patients with high-risk relapsed/refractory multiple myeloma (RRMM): A subgroup analysis from MagnetisMM-3.
Published date:
05/25/2023
Excerpt:
Subgroups analyzed were R-ISS stage (I/II/III), cytogenetic abnormalities (standard/high risk [high-risk defined by the presence of t(4;14), t(14;16) or del(17p)])….Elranatamab is efficacious and has a manageable safety profile in pts with high-risk RRMM and no prior BCMA-directed therapy.
DOI:
10.1200/JCO.2023.41.16_suppl.e20017
Trial ID:
